Compare ARK Genomic Revolution ETF (ARKG) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Consolidated Edison, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41, while Consolidated Edison, Inc. trades at $110.82 (market cap $40.95B). The key difference: Consolidated Edison, Inc. pays a 3.13% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Consolidated Edison, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | ED | |
|---|---|---|
Sector | Sector/Thematic | Utilities |
52-Week High | $43.57 | $115.46 |
52-Week Low | $23.09 | $95.37 |
Market Cap | — | $40.95B |
Enterprise Value | — | $67.98B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Consolidated Edison (ED) trades at $111.12, up 0.76% on the day, with a bullish technical signal from moving averages and support near $110. The company reported revenue of $16.92B in 2025 with a net income margin of 12.52%, though Q1 2026 EPS missed expectations. Recent news highlights grid upgrades for AI data center demand and a new board member appointment, reinforcing its steady utility profile.
ED offers a defensive investment with a 3.3% dividend yield and 52-year growth streak, but faces risks from capital-intensive grid expansions and interest rate sensitivity. Analyst consensus is cautious with a $103.50 price target below current levels, suggesting limited near-term upside amid high hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
